trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Adenomyosis D062788 1 associated lipids
Neoplasm Micrometastasis D061206 1 associated lipids
Visceral Pain D059265 1 associated lipids
Inflammatory Breast Neoplasms D058922 2 associated lipids
Capsule Opacification D058442 1 associated lipids
Intervertebral Disc Degeneration D055959 1 associated lipids
Small Cell Lung Carcinoma D055752 2 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Classical Lissencephalies and Subcortical Band Heterotopias D054221 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Rahman MM et al. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. 2003 Blood pmid:12511413
Milhem M et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. 2004 Blood pmid:14976039
Cao H et al. Induction of human gamma globin gene expression by histone deacetylase inhibitors. 2004 Blood pmid:12920038
Hebbel RP et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. 2010 Blood pmid:20053759
Hambach L et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. 2009 Blood pmid:19096014
Jamaluddin MD et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. 2007 Blood pmid:17698632
Wang X et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. 2010 Blood pmid:20858855
Li X et al. Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. 2009 Blood pmid:19864643
Gao C et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. 2013 Blood pmid:23287862
Menegola E et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. 2005 Birth Defects Res. B Dev. Reprod. Toxicol. pmid:16193500
Kalaiarasi A et al. Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. 2018 Biotechnol. Lett. pmid:29116558
Liu X et al. The improvement of adenovirus vector production by increased expression of coxsackie adenovirus receptor. 2009 Biotechnol. Lett. pmid:19330491
Kim HJ et al. Enhancement of human mesenchymal stem cell differentiation by combination treatment with 5-azacytidine and trichostatin A. 2016 Biotechnol. Lett. pmid:26341652
Seo H et al. Modulation of immunoglobulin gene conversion in chicken DT40 by enhancing histone acetylation, and its application to antibody engineering. 2007 Biotechnol. Genet. Eng. Rev. pmid:18059633
Tobias CA et al. Improved recombinant retroviral titers utilizing trichostatin A. 2000 BioTechniques pmid:11056820
Giannini G et al. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. 2009 Bioorg. Med. Chem. Lett. pmid:19285395
Lee S et al. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. 2007 Bioorg. Med. Chem. Lett. pmid:17588744
Nishino N et al. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. 2004 Bioorg. Med. Chem. Lett. pmid:15109626
Marson CM et al. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. 2004 Bioorg. Med. Chem. Lett. pmid:15109636
Vaisburg A et al. (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. 2004 Bioorg. Med. Chem. Lett. pmid:14684344
Hoque MA et al. Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. 2012 Bioorg. Med. Chem. Lett. pmid:23021104
Krennhrubec K et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. 2007 Bioorg. Med. Chem. Lett. pmid:17346959
Rajak H et al. 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. 2011 Bioorg. Med. Chem. Lett. pmid:21875796
Vaidya AS et al. Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. 2012 Bioorg. Med. Chem. Lett. pmid:23010266
Loudni L et al. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. 2007 Bioorg. Med. Chem. Lett. pmid:17624773
Wang DF et al. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. 2004 Bioorg. Med. Chem. Lett. pmid:14741273
Hirata Y et al. Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. 2012 Bioorg. Med. Chem. Lett. pmid:22321215
Desai D et al. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. 2010 Bioorg. Med. Chem. Lett. pmid:20167479
Jose B et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. 2004 Bioorg. Med. Chem. Lett. pmid:15454224
Liao V et al. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. 2012 Bioorg. Med. Chem. Lett. pmid:22932316
Pabba C et al. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. 2011 Bioorg. Med. Chem. Lett. pmid:21109435
Smil DV et al. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. 2009 Bioorg. Med. Chem. Lett. pmid:19111466
Islam NM et al. Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. 2010 Bioorg. Med. Chem. Lett. pmid:20045316
Riester D et al. Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. 2009 Bioorg. Med. Chem. Lett. pmid:19457659
Gupta PK et al. Inhibitors selective for HDAC6 in enzymes and cells. 2010 Bioorg. Med. Chem. Lett. pmid:20947351
Shinji C et al. Design and synthesis of phthalimide-type histone deacetylase inhibitors. 2005 Bioorg. Med. Chem. Lett. pmid:16137884
Uesato S et al. Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. 2002 Bioorg. Med. Chem. Lett. pmid:11992774
Hooven LA et al. Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. 2005 Bioorg. Med. Chem. Lett. pmid:15713371
Chen B et al. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. 2005 Bioorg. Med. Chem. Lett. pmid:15713393
Yu D et al. Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. 2011 Bioorg. Med. Chem. Lett. pmid:21840716
Vasudevan A et al. Heterocyclic ketones as inhibitors of histone deacetylase. 2003 Bioorg. Med. Chem. Lett. pmid:14592473
Choi E et al. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. 2011 Bioorg. Med. Chem. Lett. pmid:21256006
Nakao Y et al. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. 2008 Bioorg. Med. Chem. Lett. pmid:18397826
Mazitschek R et al. Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. 2008 Bioorg. Med. Chem. Lett. pmid:18430569
Charrier C et al. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. 2006 Bioorg. Med. Chem. Lett. pmid:16904890
Charrier C et al. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. 2007 Bioorg. Med. Chem. Lett. pmid:17897824
Van Ommeslaeghe K et al. Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. 2003 Bioorg. Med. Chem. Lett. pmid:12749885
Suzuki T et al. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. 2007 Bioorg. Med. Chem. Lett. pmid:17257837
Lavoie R et al. Design and synthesis of a novel class of histone deacetylase inhibitors. 2001 Bioorg. Med. Chem. Lett. pmid:11597413
Estiu G et al. On the inhibition of histone deacetylase 8. 2010 Bioorg. Med. Chem. pmid:20472442